This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Abbott Laboratories Corporation. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Jörg Herzogenrath: Innovator in Antibody Avidity Determination
Introduction
Jörg Herzogenrath is a notable inventor based in Hünstetten-Limbach, Germany. With a focus on medical innovations, he has made significant contributions to the field of immunology through his research and inventions. His work is particularly dedicated to the determination of antibody IgG avidity, which plays a crucial role in diagnosing various infectious diseases.
Latest Patents
His most recognized patent, entitled "Methods for the determination of antibody IgG avidity," addresses the determination of anti-infectious agent IgG avidity, specifically targeting human anti-cytomegalovirus and human anti-toxoplasma IgG avidity. The invention employs a competitive assay format that enhances the utility and accuracy of testing, which is vital for effective patient diagnosis and treatment.
Career Highlights
Jörg Herzogenrath is associated with Abbott Laboratories Corporation, a leader in the healthcare industry known for its innovative solutions. His position within the company allows him to contribute to cutting-edge research and development, particularly in the field of diagnostics. His work is recognized for its potential impact on improving diagnostic tools and patient outcomes.
Collaborations
Throughout his career, Jörg has collaborated with distinguished colleagues, including Gregory Thomas Maine and Stephen C. Hsu. These partnerships have fostered a collaborative environment that enhances innovation and promotes shared knowledge in the field of medical research.
Conclusion
Jörg Herzogenrath's contributions to antibody avidity determination mark him as a significant figure in the medical research community. His dedication to improving diagnostic methodologies through his patent and collaborative efforts underscores the importance of innovation in addressing health challenges. With ongoing support from Abbott Laboratories Corporation and his talented collaborators, his work continues to pave the way for advancements in immunological research.